Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.

Song K, Musci TJ, Caughey AB.

J Matern Fetal Neonatal Med. 2013 Aug;26(12):1180-5. doi: 10.3109/14767058.2013.770464. Epub 2013 Mar 6.

2.

Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis.

Fairbrother G, Burigo J, Sharon T, Song K.

J Matern Fetal Neonatal Med. 2016;29(7):1160-4. doi: 10.3109/14767058.2015.1038703. Epub 2015 May 22.

3.

The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.

Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN.

Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:53-61. doi: 10.1016/j.ejogrb.2014.08.028. Epub 2014 Aug 30.

PMID:
25238658
4.

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population.

Benn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M.

PLoS One. 2015 Jul 9;10(7):e0132313. doi: 10.1371/journal.pone.0132313. eCollection 2015.

5.

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis.

Neyt M, Hulstaert F, Gyselaers W.

BMJ Open. 2014 Nov 7;4(11):e005922. doi: 10.1136/bmjopen-2014-005922.

6.

Non-invasive prenatal screening for trisomy 21: what women want and are willing to pay.

Verweij EJ, Oepkes D, de Vries M, van den Akker ME, van den Akker ES, de Boer MA.

Patient Educ Couns. 2013 Dec;93(3):641-5. doi: 10.1016/j.pec.2013.08.006. Epub 2013 Aug 19.

PMID:
24011429
7.

Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.

O'Leary P, Maxwell S, Murch A, Hendrie D.

Aust N Z J Obstet Gynaecol. 2013 Oct;53(5):425-33. doi: 10.1111/ajo.12136.

PMID:
24090461
8.

A new era in prenatal care: non-invasive prenatal testing in Switzerland.

Manegold-Brauer G, Kang Bellin A, Hahn S, De Geyter C, Buechel J, Hoesli I, Lapaire O.

Swiss Med Wkly. 2014 Feb 4;144:w13915. doi: 10.4414/smw.2014.13915.

9.

Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.

Morris S, Karlsen S, Chung N, Hill M, Chitty LS.

PLoS One. 2014 Apr 8;9(4):e93559. doi: 10.1371/journal.pone.0093559. eCollection 2014.

10.

Clinical utility and cost of non-invasive prenatal testing.

Cuckle H, Benn P, Pergament E.

J Matern Fetal Neonatal Med. 2014 Feb;27(3):320-1. doi: 10.3109/14767058.2013.807239. Epub 2013 Jul 30. No abstract available.

PMID:
23875873
11.

Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.

Chitty LS, Wright D, Hill M, Verhoef TI, Daley R, Lewis C, Mason S, McKay F, Jenkins L, Howarth A, Cameron L, McEwan A, Fisher J, Kroese M, Morris S.

BMJ. 2016 Jul 4;354:i3426. doi: 10.1136/bmj.i3426.

12.

Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center.

Manegold-Brauer G, Berg C, Flöck A, Rüland A, Gembruch U, Geipel A.

Arch Gynecol Obstet. 2015 Sep;292(3):543-8. doi: 10.1007/s00404-015-3674-5. Epub 2015 Feb 26.

PMID:
25716672
13.

Use of the Combined First-Trimester Screen in High- and Low-Risk Patient Populations After Introduction of Noninvasive Prenatal Testing.

Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ.

J Ultrasound Med. 2015 Aug;34(8):1423-8. doi: 10.7863/ultra.34.8.1423.

PMID:
26206828
14.

A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program.

Ayres AC, Whitty JA, Ellwood DA.

Aust N Z J Obstet Gynaecol. 2014 Oct;54(5):412-7. doi: 10.1111/ajo.12223. Epub 2014 Sep 8.

PMID:
25196262
15.

Noninvasive prenatal testing in routine clinical practice--an audit of NIPT and combined first-trimester screening in an unselected Australian population.

McLennan A, Palma-Dias R, da Silva Costa F, Meagher S, Nisbet DL, Scott F.

Aust N Z J Obstet Gynaecol. 2016 Feb;56(1):22-8. doi: 10.1111/ajo.12432.

PMID:
26817523
16.

[MODELS OF CLINICAL IMPLEMENTATION OF CELL FREE FETAL DNA IN THE MATERNAL SERUM SCREENING TEST-ANALYSIS].

Yankova M, Chaveeva P, Stratieva V.

Akush Ginekol (Sofiia). 2015;54(7):15-21. Bulgarian.

PMID:
27025103
17.

The assessment of combined first trimester screening in women of advanced maternal age in an Asian cohort.

Li SW, Barrett AN, Gole L, Tan WC, Biswas A, Tan HK, Choolani M.

Singapore Med J. 2015 Jan;56(1):47-52.

18.
19.

Prenatal screening for fetal aneuploidy in singleton pregnancies.

Chitayat D, Langlois S, Wilson RD; Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada; Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists.

J Obstet Gynaecol Can. 2011 Jul;33(7):736-50.

PMID:
21749752
20.

Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.

Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.

Ultrasound Obstet Gynecol. 2016 Jan;47(1):45-52. doi: 10.1002/uog.15783. Epub 2015 Oct 26.

Supplemental Content

Support Center